The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
Author:
Funder
FP7 Health
Publisher
Public Library of Science (PLoS)
Subject
Multidisciplinary
Reference26 articles.
1. Chronic kidney disease: global dimension and perspectives;V Jha;Lancet,2013
2. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes;C Wanner;New England Journal of Medicine,2016
3. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications;HJL Heerspink;Circulation,2016
4. Proteomic biomarkers in kidney disease: issues in development and implementation;H Mischak;Nat Rev Nephrol,2015
5. Addressing the challenge of defining valid proteomic biomarkers and classifiers;M Dakna;BMC Bioinformatics,2010
Cited by 24 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Randomized Trial of SGLT2 Inhibitor Identifies Target Proteins in Diabetic Kidney Disease;Kidney International Reports;2024-02
2. SGLT2 Inhibitors and Diabetic Kidney Disease: Targeting Multiple and Interrelated Signaling Pathways for Renal Protection;Current Molecular Pharmacology;2023-11-28
3. Current updates on metabolites and its interlinked pathways as biomarkers for diabetic kidney disease: A systematic review;Translational Research;2023-11
4. Renal Proximal Tubular Cells: A New Site for Targeted Delivery Therapy of Diabetic Kidney Disease;Pharmaceuticals;2022-11-30
5. Dapagliflozin Improves the Urinary Proteomic Kidney-Risk Classifier CKD273 in Type 2 Diabetes with Albuminuria: A Randomized Clinical Trial;Diabetes Care;2022-08-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3